Table 5 Comparison of methylated HYP2 levels and MoM values between controls and patients with gestational hypertension with or without SGA neonates.

From: Maternal total cell-free DNA in preeclampsia with and without intrauterine growth restriction

 

Controls

Gestational hypertension (GH)

P†

Pa‡

Pb‡

Pc‡

SGA ( +)

SGA ( −)

2nd trimester

(n = 78)

(n = 4)

(n = 8)

    

Copies/mL

9,441

(5,878–12,251)

11,800

(8,661–27,875)

8,137

(4,665–9,973)

0.20

0.24

0.24

0.24

MoM

0.998

(0.952–1.026)

1.043

(0.997–1.093)

0.993

(0.911–1.012)

0.11

0.21

0.21

0.21

3rd trimester

(n = 58)

(n = 1)

(n = 6)

    

Copies/mL

14,969

(11,411–21,873)

31,699

(31,699–31,699)

23,592

(15,330–34,157)

0.21

0.46

0.46

0.81

MoM

0.979

(0.948–1.029)

1.055

(1.055–1.055)

1.014

(0.984–1.047)

0.46

0.70

0.84

0.84

  1. Data are given as median (interquartile range).
  2. Pa, GH with SGA versus controls; Pb, GH without SGA versus controls; Pc, GH with SGA versus GH without SGA.
  3. MoM multiple of the median, SGA small for gestational age.
  4. †P value by the Kruskal–Wallis test.
  5. ‡P value by the Wilcoxon rank sum test (adjusted by the step-up Bonferroni method).
Back to article page